| 21.98 -0.12 (-0.54%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 29.87  |
1-year : | 32.68 |
| Resists | First : | 25.57 |
Second : | 27.97 |
| Pivot price | 23.8 |
|||
| Supports | First : | 21.69 |
Second : | 18.05 |
| MAs | MA(5) : | 23.04 |
MA(20) : | 24.24 |
| MA(100) : | 27.45 |
MA(250) : | 22.66  |
|
| MACD | MACD : | -1.2 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 14.7 |
D(3) : | 24.5 |
| RSI | RSI(14): 31.4 |
|||
| 52-week | High : | 32.52 | Low : | 14.89 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RCKT ] has closed above bottom band by 1.1%. Bollinger Bands are 9.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.33 - 22.49 | 22.49 - 22.61 |
| Low: | 21.29 - 21.5 | 21.5 - 21.66 |
| Close: | 21.69 - 21.97 | 21.97 - 22.19 |
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Thu, 25 Apr 2024
First Week of June 21st Options Trading For Rocket Pharmaceuticals (RCKT) - Nasdaq
Wed, 24 Apr 2024
Rocket Pharmaceuticals executive sells shares worth over $19k - Investing.com India
Wed, 24 Apr 2024
Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? - Yahoo Finance
Wed, 24 Apr 2024
John Militello Sells 833 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock - MarketBeat
Tue, 23 Apr 2024
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Wed, 17 Apr 2024
Have Insiders Sold Rocket Pharmaceuticals Shares Recently? - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 91 (M) |
| Shares Float | 71 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 102.1 (%) |
| Shares Short | 10,520 (K) |
| Shares Short P.Month | 9,960 (K) |
| EPS | -2.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.46 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.1 % |
| Return on Equity (ttm) | -50.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -195 (M) |
| Levered Free Cash Flow | -122 (M) |
| PE Ratio | -7.53 |
| PEG Ratio | -0.3 |
| Price to Book value | 4.02 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|